Coated-platelets retain amyloid precursor protein on their surface

Platelets

Volumn 17, Issue 1, 2006, Pages 56-60

  Prodan, Calin I ^a,b   Szasz, Robert ^a   Vincent, Andrea S ^b   Ross, Elliott D ^a,b   Dale, George L ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Coated platelet; Collagen; Convulxin; Thrombin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CONVULXIN; PROCOAGULANT; THROMBIN;

AGONIST; ALZHEIMER DISEASE; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; COATED PARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DERIVATIZATION; HUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BLOOD PLATELETS; BLOTTING, WESTERN; CROTALID VENOMS; FEMALE; FLOW CYTOMETRY; HUMANS; LECTINS, C-TYPE; MALE; MOLECULAR WEIGHT; PLATELET ACTIVATION; SURFACE PROPERTIES; THROMBIN;

EID: 28744443584     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500181913     Document Type: Article

References (21)

1. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of ionophore A23187, thrombin, collagen and convulxin. Blood 2000;95:1694-1702.
2. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175-179.
3. Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin- derivatized proteins on COAT-platelets. Blood 2002;100:2827-2831.
4. Szasz R, Dale GL. COAT-platelets. Current Opinion in Hematology 2003;10:351-355.
5. Dale GL. Coated-platelets: An emerging component of the procoagulant response. Journal of Thrombosis and Haemostasis 2005 (in press).
6. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews 2001;81:741-766.
7. Davies TA, Fine RE, Johnson RJ, Levesque CA, Rathbun WH, Seetoo KF, Smith SJ, Strohmeier G, Volicer L, Delva L, et al. Non-age related differences in thrombin responses by platelets from male patients with advanced Alzheimer's disease. Biochemical and Biophysical Research Communications 1993;194:537-543.
8. Davies TA, Long HJ, Sgro K, Rathbun WH, McMenamin ME, Seetoo K, Tibbles H, Billingslea AM, Fine RE, Fishman JB, et al. Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiology of Aging 1997;18:147-153.
9. Davies TA, Long HJ, Tibbles HE, Sgro KR, Wells JM, Rathbun WH, Seetoo KF, McMenamin ME, Smith SJ, Feldman RG, et al. Moderate and advanced Alzheimer's patients exhibit platelet activation differences. Neurobiology of Aging 1997;18:155-162.
10. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullum CM, Weiner MF. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Archives of Neurology 1997;54:139-144.
11. Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettenati C, Mussi M, Parrinello G, et al. Amyloid precursor protein in platelets - A peripheral marker for the diagnosis of sporadic AD. Neurology 2001;57:2243-2248.
12. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 2002;59:71-75.
13. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 2000;54:1907-1909.
14. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di Luca M, Padovani A. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: A 2-year follow-up study. Archives of Neurology 2003;60:1740-1744.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC; 1987.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-198.
18. Li Q-X, Beyreuther K, Masters CL. Alzheimer's disease. In: Michelson AD, ed. Platelets. San Diego: Academic Press; 2002. pp 503-511.
19. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, Trabucchi M, Cattabeni F, Padovani A. Differential level of platelet amyloid beta precursor protein isoforms: An early marker for Alzheimer disease. Archives of Neurology 1998;55:1195-1200.
20. Rasmussen LK, Sorensen ES, Petersen TE, Gliemann J, Jensen PH. Identification of glutamine and lysine residues in Alzheimer amyloid beta A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to alpha 2M receptor. FEBS Letters 1994;338:161-166.
21. Ho GJ, Gregory EJ, Smirnova IV, Zoubine MN, Festoff BW. Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Letters 1994;349:151-154.